Jacques R. R. Mathieu

Jacques R. R. Mathieu

Auto-generated profile, based on publicly available information

Jacques R. R. Mathieu

INSERM U1279, Gustave Roussy, Villejuif, France; Université Paris Saclay, Villejuif, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Advances In Space Research
Verified
Journal Article
Closed access
LLLaurence Lebaron-Jacobs
Laurence Lebaron-Jacobs
JWJ. Wysocki
J. Wysocki
DCD. Clarendon
D. Clarendon
JMJ. Mathieu
J. Mathieu
CMC. Maubert
C. Maubert
JAJ. Aigueperse
J. Aigueperse

6 November 2025 in European Journal of Cancer
Verified
Journal Article
Open access
AMAlexia Mirandola
Alexia Mirandola
JCjerome cartry
jerome cartry
SBSabrina Bedja
Sabrina Bedja
EPEkaterina Pisareva
Ekaterina Pisareva
CPCorinne Prevostel
Corinne Prevostel
Alain ThierryAlain Thierry
Alain Thierry
Patient-derived tumor organoids (PDTOs) have histological, molecular and clinical (drug sensitivity) characteristics comparable to those of their originating tumors. However, little is known about their ability to replicate the release of tumor-derived DNA. Supernatants from 21 colorectal cancer PDTO cultures, established from 13 patients, were prospectively collected. The presence, structure, and mutational landscape of nuclear (cf-nDNA) and mitochondrial (cf-mtDNA) cell-free DNA as well as extracellular mitochondria (ex-Mito) were analyzed using qPCR, fragmentomics and shallow whole-genome sequencing. Mutation profiling was performed via IntPlex qPCR and whole-exome sequencing (WES). Cf-nDNA was detected in 95 % of PDTO supernatants with concentrations ranging from 0.009 to 209 ng/mL. Cf-nDNA fragment size analysis revealed patterns consistent with circulating DNA, including mononucleosome-associated profile. Cf-mtDNA was present in all samples (0.27-89.2 pg/mL) and extracellular mitochondria was also detected (0.009-17.4 pg/mL). A strong concordance (>85 %) was observed between oncogenic mutations in cfDNA and the molecular alterations detected in PDTOs and patient tumors. PDTOs release both nuclear and mitochondrial cfDNA into their culture medium displaying high similarity with patient-derived circulating DNA (cirDNA), including fragmentation patterns and oncogenic mutations. This study strengthens the relevance of the PDTOs as patient tumors models and highlights the potential of analyzing PDTO-derived cfDNA as a non-invasive approach to investigate tumor evolution and as a valuable tool to support functional precision oncology.

2 July 2025 in Cancer Letters
Verified
Journal Article
Open access
ALAline Lacroix
Aline Lacroix
LSLéa Swales
Léa Swales
RFRayan Farhat
Rayan Farhat
LDLaura Dadon
Laura Dadon
GRGyunel Rashidova
Gyunel Rashidova
DGDiego Germini
Diego Germini

9 June 2026 in Oncogene
Verified
Journal Article
Open access
PDF file
JLJeanne Gaspar Lopes
Jeanne Gaspar Lopes
AMAngel Markovic
Angel Markovic
CCCécile M Champy
Cécile M Champy
NANicolas Aubourg
Nicolas Aubourg
JMJacques Rr Mathieu
Jacques Rr Mathieu
virginie Firlejvirginie Firlej
virginie Firlej
Worldwide, prostate cancer (PCa) ranks second in terms of incidence and eighth in terms of mortality. While most cancers remain silent after initial treatment, some tumors recur. At present, we are unable to predict which patients are at risk of recurrence. In order to determine this risk of recurrence as early as at the biopsy stage, and to enable better therapeutic management of patients, it is essential to identify new biomarkers. In this study, we have demonstrated that Cysteine Dioxygenase CDO1 could be a predictive marker in PCa progression. Transcriptomic analysis showed that CDO1 expression is significantly reduced in patients who have relapsed and lower CDO1 expression is associated with poorer survival outcomes. In PCa, CDO1 expression could be regulated by methylation and androgen signaling pathway. Furthermore, inhibition of CDO1 expression in VCaP prostate cancer cells led to increased cell migration and non-adherent growth. Finally, transcriptomic analysis of these cells with inhibited CDO1 expression demonstrates the complex role of CDO1 and its possible involvement in the mechanisms regulating endoplasmic reticulum stress and protein unfolding. Altogether, these results describe the loss of CDO1 as a marker of aggressiveness in PCa. Furthermore, the loss of CDO1 is thought to be responsible for tumor progression in vitro by acting on multiple signaling pathways.

4 July 2026 in Nature Communications
Verified
Journal Article
Open access
NPNicolas Pasquier
Nicolas Pasquier
MPMeri Pelkonen
Meri Pelkonen
ECElise Carraz-Billat
Elise Carraz-Billat
AIAleksi Isomursu
Aleksi Isomursu
RMRaphaël Merand
Raphaël Merand
JIJohanna Ivaska
Johanna Ivaska
Mucinous colorectal carcinoma (MUC CRC) metastasis to multiple organs, and to the peritoneum, is associated with poor prognosis. Disseminating MUC CRCs exhibit either conventional (apical-in) or inverted (apical-out) polarity that influence patient outcomes. Therefore, it is critical to identify how MUC CRC polarity is regulated. Here, we analyze patient-derived MUC CRC xenografts with either apical-in or apical-out polarity. Single-cell analyses reveal α2β1-integrin as a key collagen-binding receptor in these models. Collagen–α2β1-integrin interaction activates Src and upregulates SorLA, an endosomal sorting receptor. SorLA supports apical-in polarity by promoting integrin recycling and HER2/HER3 expression. We observe positive correlation between HER2, HER3 and SorLA in patient samples and higher HER2 expression in apical-in-presenting tissues. Clinically relevant HER2/HER3-targeting antibodies revert tumor sphere polarity, and impede collagen remodeling and adhesion to mouse peritoneum. This SorLA—integrin—HER2/HER3 axis could represent a MUC CRC-patient stratification approach and be relevant for other carcinomas with apical-out phenotypes.

21 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NPNicolas Pasquier
Nicolas Pasquier
AIAleksi Isomursu
Aleksi Isomursu
HHHellyeh Hamidi
Hellyeh Hamidi
JMJacques R.R. Mathieu
Jacques R.R. Mathieu
JHJouni Härkönen
Jouni Härkönen
JIJohanna Ivaska
Johanna Ivaska
Mucinous colorectal carcinoma (MUC CRC) dissemination into the tumor stroma and metastasis to multiple organs, including the peritoneum, is associated with poor prognosis. Disseminating MUC CRCs exhibit either a conventional ‘apical-in’ or an inverted ‘apical-out’ polarity phenotype that influence patient outcome. Identifying the mechanisms controlling MUC CRC polarity is critical to understand disease progression. Here, we analyze patient-derived MUC CRC xenografts, with apical-in or apical-out polarity, ex vivo or within collagen gels to mimic the peritumoral stroma. Single-cell analyses reveal α2β1-integrin as a key collagen-binding receptor in these models. Collagen–α2β1-integrin interaction activates Src and ERK/MAPK signaling and upregulates the expression of SorLA, an endosomal sorting receptor. SorLA supports apical-in polarity and carcinoma-stroma interactions by promoting integrin recycling to the plasma membrane and HER2/HER3 expression through a positive feedback mechanism. Accordingly, we observe positive correlation between HER2, HER3 and SorLA in patient samples with the highest HER2 expression in apical-in-presenting tissues. Treatment of tumor spheres with clinically relevant HER2/HER3-targeting antibodies reverts sphere polarity and impedes collagen remodeling and adhesion to mouse peritoneum. This SorLA—integrin—HER2/HER3 signaling axis may represent a basis for MUC CRC-patient stratification and shed light on other carcinomas with similar apical-out phenotypes.